Drug Approval

In a review of the 2024 milestones, Healio | Endocrine Today compiled a list of drugs and devices related to the field that were newly approved, cleared or had label or indication changes. Information was gathered from the FDA website and news releases. We put our best effort into making a complete list and regret any omission. Appearance of a drug or device does not constitute any endorsement by Healio | Endocrine Today, its editors, publishers or editorial board. — The Editors

The FDA has granted approval to dupilumab for treating adults with poorly controlled COPD with type 2 inflammation, according to a manufacturer-issued press release.

The European Commission announced approval of dupilumab for treating adults with uncontrolled COPD with type 2 inflammation, according to a press release from Regeneron.

The FDA approved Kisunla for adults with early symptomatic Alzheimer’s disease, including those with mild cognitive impairment and mild dementia with confirmed amyloid pathology.

Less than half of the cancer therapies granted FDA accelerated approval showed meaningful improvement in survival or quality-of-life, study results presented at American Association for Cancer Research Annual Meeting showed.

In a video interview, Majda Hadziahmetovic, MD, retinal specialist and assistant professor of ophthalmology at Duke University discusses the FDA's approval of two new wet AMD treatments and the introduction of biosimilars into the field.

Healio has compiled the most-read news in pulmonology posted in March.

The FDA has approved sotatercept, an activin signaling inhibitor, for treating adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.

The European Commission has approved Hyqvia as maintenance therapy for individuals of all ages with chronic inflammatory demyelinating polyneuropathy.

Five obesity advocacy organization have issued a joint statement asking the FDA to mandate that all drug approval trials include people with obesity.